is a strategic platform for discussion and collaboration among decision makers, researchers and technologists who understand and follow this tendency. The event is taking place on 18-19 November in Zurich to facilitate the exchange of ideas and best practices helping to further integrate digital advancements into pharmaceutical research and development as well as shape the future of the industry. Let’s briefly review the key topics to be discussed during the Congress.
Implementing AI for valuable insights
Artificial intelligence (AI) and machine learning (ML) are instrumental in shaping digital transformation. These technologies enable the analysis of vast datasets to identify potential drug candidates, predict their efficacy and anticipate possible side effects. For instance, AI algorithms can rapidly screen millions of compounds, significantly speeding up the initial phases of drug discovery.
SCARLETRED Holding GmbH, a digital health company, is implementing AI to revolutionise dermatological drug development. During the AUTOMA+ Congress, Harald Schnidar (CEO) is going to share how the company is breaking the boundaries between human and machine in skin drug research. Their AI-powered platform, Scarletred Vision, uses advanced image analysis to assess and monitor skin conditions with high precision. By capturing and analysing high-resolution images, the AI can objectively measure treatment efficacy and disease progression, not only speeding up the research process but also enhancing the accuracy and reliability of clinical trials.
Effective Data Analytics and Management
As the pharmaceutical industry increasingly adopts digital technologies and data-driven approaches, the ability to manage large volumes of diverse data, ranging from clinical trial results to manufacturing processes, becomes essential. Effective data analytics and management practices support regulatory submissions, streamline research and development processes, and enhance decision-making.
Karol Teliscak, Digital & IT Business Partnering Manager at Debiopharm International SA, is joining the Congress to speak on how the company leverages its Central Data Repository to transform clinical data management. This centralised system integrates data from multiple clinical trials, providing a unified tool for data storage, retrieval, and analysis. The repository allows for real-time monitoring and analysis of clinical trial data, facilitating more informed and timely decisions in the drug development process.
CSL Behring, a global biopharmaceutical company, has adopted advanced data management strategies to optimise its clinical trials and research efforts. As a speaker at AUTOMA+ 2024, Bárbara Fernandes de Souza (Digital Operations Specialist) is going to unveil CSL Behring’s approach on driving operations through digital solutions and data management. For instance, the company utilises a sophisticated data integration platform that consolidates information from various sources, including electronic data capture, clinical trial and laboratory information management systems.
By implementing these technologies, the companies can rapidly identify trends, monitor patient safety, and make data-driven decisions that enhance the overall quality and speed of the drug discovery and development process.
Advanced Cellular ÍøÆØÃÅ
Advanced cellular analysis is transforming the landscape of drug discovery by providing unprecedented insights into cellular behaviour and drug interactions. Utilising cutting-edge imaging technologies and AI-driven analytics, researchers can observe and analyse cellular processes in real-time and at high resolution. This approach allows for detailed visualisation of cell health, proliferation, and response to treatments, helping to identify the most promising drug candidates more quickly and accurately.
CellVoyant, an AI-first biotechnology company, is pioneering innovations in cellular analysis. Saad Mohamad (ML science Lead) is joining the discussion at AUTOMA+ 2024 to explain how the company is moving towards self-driving development of cell therapies. Their technology captures high-resolution images and employs sophisticated AI algorithms to analyse cellular activities and interactions. This detailed data accelerates the identification of effective drug candidates and helps in understanding the mechanisms of action at a cellular level.
AUTOMA+ 2024: where challenges become opportunities
The impact of digital technologies on pharmaceutical research and development processes is profound and far-reaching. As innovations like AI and data management continue to evolve, they will further streamline drug discovery and development processes, leading to more effective and personalised therapies.
Gathering leading pharmaceutical companies that embrace digital transformation, the AUTOMA+ community ensures that the industry moves towards greater efficiency, innovation and compliance in an increasingly complex regulatory environment. By focusing on cutting-edge automation technologies, data-driven decision-making and the integration of AI and machine learning, the Congress empowers participants to address the challenges of modern pharmaceutical development.
Learn more about the event:
